Sangamo Therapeutics (SGMO) Invested Capital (2016 - 2025)
Historic Invested Capital for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $6.2 million.
- Sangamo Therapeutics' Invested Capital fell 8404.71% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year decrease of 8404.71%. This contributed to the annual value of $22.8 million for FY2024, which is 7252.89% down from last year.
- As of Q3 2025, Sangamo Therapeutics' Invested Capital stood at $6.2 million, which was down 8404.71% from $19.6 million recorded in Q2 2025.
- In the past 5 years, Sangamo Therapeutics' Invested Capital registered a high of $469.4 million during Q1 2021, and its lowest value of $4.9 million during Q1 2025.
- Moreover, its 5-year median value for Invested Capital was $233.6 million (2023), whereas its average is $206.0 million.
- As far as peak fluctuations go, Sangamo Therapeutics' Invested Capital surged by 1901.6% in 2021, and later crashed by 9134.7% in 2025.
- Sangamo Therapeutics' Invested Capital (Quarter) stood at $375.3 million in 2021, then dropped by 21.42% to $295.0 million in 2022, then tumbled by 71.9% to $82.9 million in 2023, then tumbled by 72.53% to $22.8 million in 2024, then tumbled by 72.58% to $6.2 million in 2025.
- Its Invested Capital was $6.2 million in Q3 2025, compared to $19.6 million in Q2 2025 and $4.9 million in Q1 2025.